Hisham Shiblaq served as Executive Vice President and Chief Commercial Officer at PROCEPT BioRobotics Corporation, a pioneering medical device company specializing in robotic-assisted therapies for urological conditions. In this pivotal role, he spearheaded the company's global commercial strategy, overseeing sales, marketing, market access, and customer operations. Shiblaq played a key role in accelerating the adoption of PROCEPT's flagship Aquablation therapy, driving U.S. revenue growth from under $50 million to over $150 million annually during his tenure, while expanding the commercial team from 100 to more than 400 professionals. With over 25 years of experience in the medtech industry, Shiblaq previously held senior leadership positions at Boston Scientific, where he led the Endoscopy division's commercial expansion in the Americas, and at Intuitive Surgical, contributing to the da Vinci Surgical System's market penetration. His expertise in scaling high-growth organizations and launching disruptive technologies has earned him recognition, including MedTech Strategist’s "Circle of Excellence" award. Shiblaq's strategic vision focused on physician education, reimbursement strategies, and international market entry, positioning PROCEPT for sustained leadership in robotic urology. Shiblaq's tenure at PROCEPT culminated in transformative achievements, such as securing key reimbursement codes and forging partnerships that broadened Aquablation's reach to over 200 U.S. centers. A proven leader in building high-performance cultures, he emphasized data-driven commercialization and customer-centric innovation, leaving a lasting impact on the company's trajectory toward becoming a multi-billion-dollar enterprise.